Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

[Sphingosine-1-phosphate signaling system and the innovative mechanism of action of fingolimod in treatment of multiple sclerosis: review of foreign literature.]
Therapeutic effet of phase ii enzyme inducers in experimental allergic encephalomyelitis (eae).
Oligoclonal bands and cerebrospinal fluid markers in multiple sclerosis: associations with disease course and progression.
Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness.
MRI measures should be a primary outcome endpoint in phase III randomised controlled trials in multiple sclerosis: Commentary.
A phase-specific neuroimmune model of clinical depression.
Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function.
A case with neuromyelitis optica mimicking Susac's syndrome.
Prevalence and Significant Determinants of Post-traumatic Stress Disorder in a Large Sample of Patients with Multiple Sclerosis.
[New therapies in multiple sclerosis].
Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis.
Parkinsonism in multiple sclerosis patients: A casual or causal association?
Protection of tregs, suppression of Th1 and th17 cells, and amelioration of experimental allergic encephalomyelitis by a physically-modified saline.
Patients' experiences of health and social care in long-term neurological conditions in England: a cross-sectional survey.
Contribution of vitamin D insufficiency to the pathogenesis of multiple sclerosis.
Network-Based Multiple Sclerosis Pathway Analysis with GWAS Data from 15,000 Cases and 30,000 Controls.
Network Analysis of Randomized Controlled Trials in Multiple Sclerosis.
Inducible Foxp3+ regulatory T-cell development by a commensal bacterium of the intestinal microbiota.
FTY720 protects neuronal cells from damage induced by human prion protein by inactivating the JNK pathway.
Effectiveness of Energy-Conservation treatment in reducing fatigue in Multiple Sclerosis: a systematic review and meta-analysis.
Pharmacological effects of CS-0777, a selective sphingosine 1-phosphate receptor-1 modulator: Results from a 12-week, open-label pilot study in multiple sclerosis patients.
Homonymous hemimacular thinning: a unique presentation of optic tract injury in neuromyelitis optica.
CC3-03: Drug Characteristics Associated with Medication Adherence Across Eight Disease States.
Placebo power.
Targeting NOX enzymes in the central nervous system: therapeutic opportunities.

Pages